Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants (HYFIVE Trial): A Randomized Clinical Trial

Saturday, April 23, 2022

2:15 PM – 2:30 PM US MT

Location: Convention Center: Mile High Ballroom 3AB

CE: Enduring CME: 0.25

Publication Number: 1545.6

Colm P. Travers, University of Alabama at Birmingham, Birmingham, AL, United States; Samuel Gentle, UAB, Birmingham, AL, United States; Vivek V. Shukla, University of Alabama at Birmingham, Birmingham, AL, United States; Deborah J. Laney, University of Alabama School of Medicine, Birmingham, AL, United States; Aaron Yee, NemoursAlfred I. duPont Hospital for Children, Wilmington, DE, United States; Namasivayam Ambalavanan, University of Alabama School of Medicine, Birmingham, AL, United States; Waldemar A. Carlo, University of Alabama at Birmingham, Birmingham, AL, United States

Presenting Author(s)

Colm P. Travers, MD
Assistant professor
University of Alabama at Birmingham
Birmingham, Alabama, United States

Full Presentation

Participants should be aware of the following financial/non-financial relationships:

Colm P. Travers, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Samuel Gentle, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Vivek V. Shukla, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Deborah J. Laney, MSN: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Aaron Yee, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Namasivayam Ambalavanan, MBBS MD: ● ProvePharm (Currently Ongoing) (Products/Services: Consultant).
● Radiometer (Currently Ongoing) (Products/Services: Consultant).
● ResBiotic (Currently Ongoing) (Products/Services: Advisory Committee).
● Shire (Currently Ongoing) (Products/Services: Consultant).

Waldemar A. Carlo, MD: ● Mednax (Currently Ongoing) (Products/Services: Board Member or Executive Role, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).